Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report


TAÇOY G. , Cengel A., ÖZKURT Z. N. , TÜRKOĞLU S.

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, cilt.43, sa.1, ss.78-81, 2015 (ESCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 43 Konu: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.5543/tkda.2015.41763
  • Dergi Adı: TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
  • Sayfa Sayıları: ss.78-81

Özet

Pulmonary hypertension (PHT) is a pathological condition determined as an increase in mean pulmonary arterial pressure >= 25 mmHg. Pulmonary arterial hypertension (PAH) is precapillary PHT and a life-threatening disease group which consists of different etiologies with the same pathological and clinical findings, and which is characterized by elevated pulmonary vascular resistance. Dasatinib is a dual Src/Abl kinase inhibitor associated with higher affinity for BCR/ABL kinase than imatinib, and is used in the treatment of chronic myelocytic leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). We describe a case with ALL, in whom dasatinib treatment induced PAH, and who recovered with bosentan treatment.